INTRODUCTION
============

Androgenic alopecia causes hair loss by shortening the growth phase (anagen) of hair follicles; it is provoked by excessive androgen-receptor activation by androgens such as testosterone and dihydrotestosterone (DHT) in post-pubertal males[@B1][@B2][@B3]. Androgen-induced regulation of the hair growth cycle results in early growth cessation (catagen)[@B4]. Specifically, DHT produced by 5α-reductase strongly activates the androgen receptors, because its binding affinity is two to three times that of testosterone[@B5][@B6]. The activity or expression of 5α-reductase is elevated in most cases of androgenic alopecia[@B7]. Therefore, 5α-reductase and androgen receptors are attractive therapeutic targets for that condition[@B8][@B9]. The DHT-mediated activation of androgen receptors induces the expression of various downstream genes that are related to hair follicle development, morphology, and cell cycling[@B10][@B11].

In a recent study, DHT was shown to regulate microRNAs (miRNAs) in dermal papilla cells (DPCs), a group of specialized fibroblasts within the hair follicle bulb[@B12]. Additionally, miRNAs exhibit altered expression profiles in the balding dermal papilla[@B13]. miRNAs are small, non-coding RNAs containing 19\~24 nucleotides. They target specific sequences within messenger RNAs (mRNAs) and repress mRNA translation, thus playing important roles in the development, cell cycle regulation, apoptosis, differentiation, and cell proliferation[@B12][@B13][@B14].

Epigallocatechin gallate (EGCG), a representative ingredient in green tea, is a major polyphenolic constituent used widely for its anti-cancer effects, protection against ultraviolet light-induced DNA damage, and antioxidant and anti-inflammation activities[@B15][@B16][@B17][@B18][@B19][@B20]. In hair follicles, EGCG prevents androgenic alopecia by inhibiting 5α-reductase activity[@B21]. EGCG promotes hair growth by activating Erk and Akt signaling and increasing the B-cell lymphoma 2 (BCL2)/Bax ratio in DPCs[@B22]. Additionally, it has been reported that EGCG protects against ultraviolet light-mediated cell death and cell cycle arrest by regulating specific miRNAs[@B23]. Here, we demonstrate that EGCG protects against DHT-induced cell death, cell cycle arrest, senescence, and oxidative stress in human DPCs by inducing changes in the miRNA expression profile.

MATERIALS AND METHODS
=====================

Chemicals and cell culture
--------------------------

EGCG and DHT were purchased from Sigma-Aldrich (St. Louis, MO, USA). Human DPCs (Innoprot, Biscay, Spain), characterized and isolated from the frontal head region of a non-balding male 34 years of age, were maintained in Dulbecco\'s minimal essential medium (DMEM; Gibco/Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Sigma-Aldrich), 100 IU/ml penicillin, and 100 µg/ml streptomycin. The cultures were incubated at 37℃ in a humidified atmosphere of 5% CO~2~.

Cell viability assay
--------------------

Human DPCs were seeded in 96-well plates (5×10^3^ cells per well) in triplicate. After 24 hours, the cells were exposed to the indicated concentrations of DHT and EGCG. To assess the cell viability, the cells were incubated in a water soluble tetrazolium salt (WST-1) solution for 30 minutes, and the optical density at 490 nm was subsequently measured.

Cell cycle analysis
-------------------

Human DPCs (2×10^6^ cells) were seeded in 60 mm culture dishes and cultured for 24 hours in DMEM. The cells were then treated with DHT and EGCG for 24 hours. Then, the cells were digested with 0.25% trypsin (Gibco/Life Technologies), fixed with 70% ethanol for 3 hours, and stained with propidium iodide (PI; Sigma-Aldrich). After 1 hour incubation, the cells were washed with phosphate-buffered saline, and a FACSCaliber flow cytometer (BD Biosciences, San Jose, CA, USA) was used to analyze their fluorescence intensity in the FL2 channel (excitation wavelength, 488 nm; emission wave-length, 578 nm).

Intracellular reactive oxygen species analysis
----------------------------------------------

Human DPCs (2×10^6^ cells) were seeded in 60 mm culture dishes and cultured for 24 hours in DMEM. They were then treated with DHT and EGCG as indicated for 24 hours. Next, 20 µM 2\',7\'-dichlorofluorescein diacetate (Sigma-Aldrich) was added to the culture medium for 1 hour. The cells were then digested with 0.25% trypsin and washed with phosphate-buffered saline. The stained cells were analyzed using a FACSCaliber flow cytometer (BD Biosciences) with the FL1 channel (excitation wavelength, 488 nm; emission wavelength, 530 nm).

Cell senescence analysis
------------------------

Human DPCs (2×10^6^ cells) were seeded in 60 mm culture dishes and cultured for 24 hours in DMEM. They were then treated with DHT and EGCG as indicated for 48 hours. Next, the cells were fixed and stained with a senescence detection kit (Biovision, Milpitas, CA, USA) and observed under a light microscope (Olympus DSU, Tokyo, Japan).

Total RNA extraction and miRNA expression profile
-------------------------------------------------

Total cellular RNA was isolated with TRIzol reagent (Invitrogen/Life Technologies, Grand Island, NY, USA) according to the manufacturer\'s instructions. miRNA labeling, hybridization, and microarray analyses were performed as described previously[@B24]. The isolated RNAs were labeled with Cy3 using the Agilent miRNA labeling kit (Agilent Technologies, Santa Clara, CA, USA). The labeled RNAs were purified using Micro Bio-Spin P-6 columns (Bio-Rad Laboratories, Hercules, CA, USA). For the miRNA expression profile, the SurePrint G3 Human V16 miRNA 8×60 K array (Agilent Technologies), including 1205 annotated miRNA sequences, was hybridized with the labeled total cellular RNA at 65℃ for 20 hours. The microarray was scanned using an Agilent Microarray Scanner (Agilent Technologies), and the images were analyzed using the Agilent Feature Extraction Software (Agilent Technologies). A signal analysis of the microarrays (GeneSpring GX ver. 11.5, Agilent Technologies) compared the fluorescence intensities between samples obtained from control and EGCG-treated human DPCs, respectively.

Bioinformatics analysis and target prediction
---------------------------------------------

The PITA (<http://genie.weizmann.ac.il>), microRNAorg (<http://www.microrna.org>), and TargetScan (<http://www.targetscan.org>) online software programs were used for bioinformatics analysis and miRNA target prediction. The gene ontologies (GOs) of the putative target genes were analyzed using the Database for Annotation, Visualization, and Integrated Discovery Bioinformatics Resource 6.7 (<http://david.abcc.ncifcrf.gov>).

Statistical analysis
--------------------

The data are presented as the mean±standard deviation. Statistical significance was calculated using Student\'s two-tailed t-test, and *p*\<0.01 was considered statistically significant unless otherwise indicated.

RESULTS
=======

EGCG attenuated DHT-induced growth arrest in human DPCs
-------------------------------------------------------

To determine the effect of EGCG on the cytotoxicity of DHT in human DPCs, we performed cell viability assays. The cell viability increased with 10 µM EGCG, but it decreased with EGCG concentrations ≥20 µM ([Fig. 1A](#F1){ref-type="fig"}). That result corroborates a previous finding that EGCG has concentration-dependent dual functions[@B25]. Next, we investigated whether EGCG protected against DHT-induced growth arrest. EGCG (0\~15 µM) attenuated DHT-induced growth arrest in the human DPCs in a dose-dependent manner ([Fig. 1B](#F1){ref-type="fig"}). All three of the EGCG doses tested produced significant protective effects. In addition, EGCG decreased levels of DHT-mediated cell death ([Fig. 1C](#F1){ref-type="fig"}). Overall, DHT decreased cell viability, but the EGCG treatments rescued the DHT-mediated decrease in cell viability by repressing cell death.

EGCG ameliorated DHT-induced reactive oxygen species levels and senescence in human DPCs
----------------------------------------------------------------------------------------

EGCG ameliorated the DHT-mediated elevation of intracellular reactive oxygen species (ROS) levels ([Fig. 2A](#F2){ref-type="fig"}). Because intracellular ROSs are involved in inducing senescence[@B11], we investigated whether EGCG inhibited senescence in human DPCs by quantifying the activity of senescence-associated β-gal. As shown in [Fig. 2B](#F2){ref-type="fig"}, EGCG significantly inhibited DHT-induced senescence.

EGCG altered miRNA expression profiles in DHT-treated human DPCs
----------------------------------------------------------------

Finally, we assessed whether EGCG altered miRNA expression profiles in DHT-treated human DPCs. Recent studies have shown that EGCG is a natural regulator of miRNAs that can influence cell growth, apoptosis, and cell cycle regulation. Among the 1205 annotated miRNAs analyzed, 13 miRNAs showed up-regulation by more than twofold, and 40 miRNAs showed down-regulation by more than twofold after EGCG administration to DHT-treated human DPCs ([Table 1](#T1){ref-type="table"}).

Using three bioinformatics and target prediction systems, we identified target genes of 54 miRNAs that were up-regulated or down-regulated by the EGCG treatment in DHT-treated human DPCs ([Table 2](#T2){ref-type="table"}). Overall, we analyzed 306 putative target genes of 13 up-regulated miRNAs and 134 putative target genes of 40 down-regulated miRNAs. Next, we identified the biological roles of the putative target genes by GO analysis. The putative target genes were classified into five major functional categories: anti-oxidation, apoptosis and cell death, proliferation and cell growth, aging, and cell cycle-related ([Fig. 3](#F3){ref-type="fig"}). The protective effects of EGCG against DHT-mediated growth arrest, cell death, increased ROS, and senescence were strongly associated with the altered miRNA expression profile.

DISCUSSION
==========

In the present study, we showed the biological effects of EGCG and EGCG-mediated changes in miRNA profiles in DHT-exposed human DPCs. EGCG is a well-known, dual-role agent that protects against cellular damage in impaired cells and also induces cell death in various tumors[@B26][@B27][@B28][@B29][@B30][@B31]. We investigated whether EGCG reduced DHT-mediated cellular damage in human DPCs. The results shown in [Figs. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"} suggest that EGCG inhibits DHT-induced cell death, intracellular ROS levels, and senescence. In general, DHT increases intracellular ROS levels, which induce cell death and growth arrest[@B32][@B33]. EGCG, a powerful antioxidant, ameliorated the DHT-mediated elevation of intracellular ROS levels and thus protected the human DPCs[@B17]. EGCG treatment alone slightly increased the sub-G1 cell population, however, which suggests that EGCG induced some cell death under normal conditions ([Fig. 1C](#F1){ref-type="fig"}). Several previous studies have shown that high concentrations of EGCG induce cell death and cell cycle arrest in various cancers[@B28][@B29][@B30][@B31]. Lu et al.[@B34] showed that EGCG can induce cell death at low concentrations (\<100 µM) in normal human lung and skin cells, because antioxidants such as EGCG eliminate intercellular ROSs used as signal molecules[@B34][@B35]. Thus, low concentrations of EGCG can induce some degree of cell death under normal conditions.

We showed the effects of EGCG on the miRNA profile in DHT-exposed human DPCs. EGCG significantly up-regulated or down-regulated 53 miRNAs. Previous studies have identified direct target genes and physiological roles in some of those miRNAs. Hsa-miR-210 (330.95-fold increase) promotes proliferation and represses growth arrest through the targeting of fibroblast growth factor receptor-like 1 (FGFRL1), apoptosis-inducing factor, mitochondrion-associated 3 (AIFM3), stathmin (STMN1), probable dimethyladenosine transferase (DIMT1), protein tyrosine phosphatase non-receptor type 2 (PTPN2), and iron-sulfur cluster scaffold homolog 2 (ISCU2)[@B36][@B37][@B38][@B39]. Hsa-miR-590-5p (147.55-fold increase) promotes cell growth and survival by targeting the S100 calcium-binding protein A10 (S100A10), transforming growth factor beta receptor II (TGF-β RII), and close homolog of L1 (CHL1)[@B40][@B41][@B42]. The overexpression of hsa-miR-370 (2.22-fold increase) induces proliferation by interfering with forkhead box protein O1 (FOXO1)[@B43][@B44]. Hsa-miR-188-5p (147.60-fold decrease) suppresses the G1/S transition by targeting cyclin D1 (CCND1), CCND3, CCNE2, CCNA2, cyclin-dependent kinase 4 (CDK4), and CDK2[@B45]. Hsa-miR-28-5p (49.61-fold decrease) targets MAD2 mitotic arrest deficient-like 1 (MAD2L1), BCL2-associated athanogene (BAG1), and the rat sarcoma viral oncogene homolog (RAS) oncogene family (RAP1B and RAB23)[@B46], which can regulate cell proliferation, migration, and invasion by influencing spindle checkpoint control, apoptosis, and GTPase-mediated signal transduction.

Furthermore, we predicted the targets of a number of the EGCG-regulated miRNAs using Targetscan, PITA, and microRNAorg ([Table 2](#T2){ref-type="table"}). Many of the predicted target genes are associated with pathways regulating anti-oxidation, apoptosis and cell death, proliferation and cell growth, aging, and the cell cycle ([Fig. 3](#F3){ref-type="fig"}). Our results show that the EGCG-mediated regulation of those regulatory pathways is related to alterations of miRNA expression in DHT-exposed human DPCs.

Overall, our investigation revealed EGCG-mediated changes in miRNA expression that protect against the DHT-induced human DPC phenotype. Our microarray analyses show that EGCG modulates the expression of miRNAs involved in oxidation, apoptosis and cell death, proliferation and cell growth, aging, and the cell cycle, providing an overall protective effect against DHT.
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![Effects of epigallocatechin gallate (EGCG) on human dermal papilla cell (DPC) viability and cell cycle progression. Human DPCs were treated with different concentrations of EGCG (A) or EGCG and dihydrotestosterone (DHT) (B) for 24 hours before water soluble tetrazolium salt (WST-1) assays to measure viability. (C) Human DPCs were treated with 10 µM EGCG or 10^--4^ M DHT for 24 hours before they were washed and stained with propidium iodide (PI; Sigma-Aldrich, St. Louis, MO, USA). The fluorescence intensity distributions of the stained cells were analyzed by flow cytometry (left) and the proportions of the cells in Sub-G1 phase were determined (right). Cells in the Sub-G1, G1, S, and G2/M phases were separated using the gates M1, M2, M3, and M4, respectively. Viability data are expressed as percentages of the viability of the internal control (untreated sample) and are shown as the mean±standard error of the mean of three independent experiments. ^\#^*p*\<0.05 compared with vehicle, ^\*^*p*\<0.05 compared with DHT.](ad-28-327-g001){#F1}

![Effects of epigallocatechin gallate (EGCG) on intracellular reactive oxygen species (ROS) levels and cellular senescence in human dermal papilla cells (DPCs). (A) Human DPCs were grown with or without 10 µM EGCG and 10^--4^ M dihydrotestosterone (DHT). To detect intracellular ROS levels, we performed 2\',7\'-dichlorofluorescein diacetate staining and detected cell cycle changes using a FACScalibur flow cytometer (BD Biosciences, San Jose, CA, USA). Changes in intracellular ROS levels were determined with the M1 gate. (B) Cells were treated with 10 µM EGCG or 10^--4^ M DHT for 48 hours. Senescence was measured using senescence- associated β-gal assays. Senescence data are expressed as percentages of the senescence of the internal control (untreated sample) and are shown as the mean±standard error of the mean of three independent experiments. PI: propidium iodide (Sigma-Aldrich, St. Louis, MO, USA). ^\#^*p*\<0.05 compared with vehicle, ^\*^*p*\<0.05 compared with DHT.](ad-28-327-g002){#F2}

![Gene ontology classification of predicted target genes of microRNAs affected by epigallocatechin gallate in dihydrotestosterone-treated human dermal papilla cells. GO terms 1\~5 are related to anti-oxidation: 1-oxidoreduction coenzyme metabolic process (GO:0006733); 2-response to oxidative stress (GO:0006979); 3-response to hydrogen peroxide (GO:0042542); 4-energy derivation by oxidation of organic compounds (GO:0015980); 5-oxidation reduction (GO:0055114). GO terms 6\~22 are related to apoptosis and cell death: 6-anti-apoptosis (GO:0006916); 7-induction of apoptosis by extracellular signals (GO:0008624); 8-regulation of apoptosis (GO:0042981); 9-negative regulation of apoptosis (GO:0043066); 10-positive regulation of apoptosis (GO:0043065); 11-induction of apoptosis (GO:0006917); 12-apoptosis (GO:0006915); 13-regulation of programmed cell death (GO:0043067); 14-regulation of cell death (GO:0010941); 15-negative regulation of programmed cell death (GO:0043069); 16-negative regulation of cell death (GO:0060548); 17-positive regulation of programmed cell death (GO:0043068); 18-positive regulation of cell death (GO:0010942); 19-induction of programmed cell death (GO:0012502); 20-cell death (GO:0008219); 21-death (GO:0016265); 22-programmed cell death (GO:0012501). GO terms 23\~33 are related to proliferation and cell growth: 23-cell proliferation (GO:0008283); 24-positive regulation of cell proliferation (GO:0008284); 25-regulation of cell proliferation (GO:0042127); 26-negative regulation of cell proliferation (GO:0008285); 27-negative regulation of cell growth (GO:0030308); 28-regulation of growth (GO:0040008); 29-regulation of developmental growth (GO:0048638); 30-negative regulation of growth (GO:0045926); 31-regulation of cell growth (GO:0001558); 32-positive regulation of growth (GO:0045927); 33-growth (GO:0040007). GO term 34 is related to aging (34-aging (GO:0007568). GO terms 35\~48 are related to the cell cycle: 35-regulation of cell cycle (GO:0051726); 36-negative regulation of cell cycle (GO:0045786); 37-M phase of meiotic cell cycle (GO:0051327); 38-meiotic cell cycle (GO:0051321); 39-negative regulation of mitotic cell cycle (GO:0045930); 40-negative regulation of cell cycle process (GO:0010948); 41-regulation of mitotic cell cycle (GO:0007346); 42-cell cycle phase (GO:0022403); 43-regulation of cell cycle process (GO:0010564); 44-cell cycle (GO:0007049); 45-cell cycle process (GO:0022402); 46-mitotic cell cycle (GO:0000278); 47-cell cycle checkpoint (GO:0000075); 48-M phase of mitotic cell cycle (GO:0000087).](ad-28-327-g003){#F3}

###### miRNAs from hDPCs with \>2 fold expression change following EGCG and DHT treatment

![](ad-28-327-i001)

  miRNA               Fold change   Direction of change to control   Chr     miRNA             Fold change   Direction of change to control   Chr
  ------------------- ------------- -------------------------------- ------- ----------------- ------------- -------------------------------- -------
  hsa-miR-181b        2.17          Up                               chr1    hsa-miR-17^\*^    −82.18        Down                             chr13
  hsa-miR-181d        137.76        Up                               chr19   hsa-miR-1825      −126.92       Down                             chr20
  hsa-miR-210         330.95        Up                               chr11   hsa-miR-186       −61.81        Down                             chr1
  hsa-miR-3656        2.26          Up                               chr11   hsa-miR-188-5p    −147.60       Down                             chrX
  hsa-miR-370         2.22          Up                               chr14   hsa-miR-18b^\*^   −56.14        Down                             chrX
  hsa-miR-4257        66.47         Up                               chr1    hsa-miR-202       −47.66        Down                             chr10
  hsa-miR-4270        2.88          Up                               chr3    hsa-miR-204       −55.37        Down                             chr9
  hsa-miR-4271        2.17          Up                               chr3    hsa-miR-28-5p     −49.61        Down                             chr3
  hsa-miR-4327        4.05          Up                               chr21   hsa-miR-3180-5p   −53.64        Down                             chr16
  hsa-miR-590-5p      147.55        Up                               chr7    hsa-miR-324-5p    −49.46        Down                             chr17
  hsa-miR-629^\*^     140.42        Up                               chr15   hsa-miR-33b^\*^   −26.10        Down                             chr17
  hsa-miR-718         104.88        Up                               chrX    hsa-miR-3613-3p   −106.25       Down                             chr13
  hsa-miR-762         2.12          Up                               chr16   hsa-miR-3676      −135.08       Down                             chr17
  hsa-let-7a^\*^      −38.70        Down                             chr9    hsa-miR-369-3p    −49.41        Down                             chr14
  hsa-miR-100^\*^     −51.87        Down                             chr11   hsa-miR-3907      −2.66         Down                             chr7
  hsa-miR-1225-3p     −2.00         Down                             chr16   hsa-miR-411^\*^   −29.26        Down                             chr14
  hsa-miR-1249        −48.55        Down                             chr22   hsa-miR-425^\*^   −125.74       Down                             chr3
  hsa-miR-128         −48.31        Down                             chr2    hsa-miR-4306      −121.68       Down                             chr13
  hsa-miR-1281        −104.56       Down                             chr22   hsa-miR-431       −48.51        Down                             chr14
  hsa-miR-129-3p      −58.90        Down                             chr11   hsa-miR-431^\*^   −34.81        Down                             chr14
  hsa-miR-136         −2.09         Down                             chr14   hsa-miR-4317      −52.71        Down                             chr18
  hsa-miR-138-2^\*^   −71.90        Down                             chr16   hsa-miR-550a      −25.75        Down                             chr7
  hsa-miR-146a        −49.51        Down                             chr5    hsa-miR-664       −140.38       Down                             chr1
  hsa-miR-150^\*^     −54.57        Down                             chr19   hsa-miR-766       −2.38         Down                             chrX
  hsa-miR-1539        −55.61        Down                             chr18   hsa-miR-770-5p    −77.43        Down                             chr14
  hsa-miR-16-2^\*^    −26.03        Down                             chr3    hsa-miR-933       −31.12        Down                             chr2

miRNA: microRNA, hDPC: human dermal papillary cell, EGCG: epigallocatechin gallate, DHT: dihydrotestosterone, chr: chromosome.

###### Number of targets of selected miRNAs based on three prediction databases

![](ad-28-327-i002)

  Targets of up-regulated miRNAs                           Targets of down-regulated miRNAs                                           
  -------------------------------------------------------- -------------------------------------------------------- ----- ----- ----- -----
  673                                                      415                                                      833   535   173   470
  Intersection of three target prediction databases: 306   Intersection of three target prediction databases: 134                     

TargetScan: <http://www.targetscan.org>, PITA: <http://genie.weizmann.ac.il>, microRNAorg: <http://www.microrna.org>, miRNAs: microRNAs.
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